Application No.: 09/816,839
Attorney Docket No.: TNX 00-04
Customer No.: 26839

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-18 (Canceled)

19. (Currently Amended) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which inhibits complement activation at a molar ratio of ~~about~~ 1:2 (antibody to C2).

20. (Previously Presented) An antibody that binds to C2a or the C2a portion of C2, or a C2a binding fragment thereof, which inhibits both the classical and the lectin complement pathways at a molar ratio of about 1:2 (antibody to C2).

21. (Canceled)

22. (Previously Presented) The antibody of claim 19, wherein the antibody fragment is a Fab, $F(ab')_2$, Fv or single chain Fv.

23. (Previously Presented) The antibody of claim 19, wherein the antibody is monoclonal.

24. (Previously Presented) The monoclonal antibody of claim 23, wherein the antibody is a chimeric, deimmunized, humanized or a human antibody.

25. (Previously Presented) A monoclonal antibody 175-62.

26. (Previously Presented) A cell line that produces the monoclonal antibody 175-62.

27. (Previously Presented) A pharmaceutical composition comprising the antibody of claim 19 and a pharmacologically acceptable carrier, excipient, stabilizer, or diluent.

28. (Currently Amended) A method of inhibiting complement activation comprising administering ~~an antibody that binds C2a or the C2a portion of C2~~ the antibody of claim 19 or claim 20.

29. (Currently Amended) A method of inhibiting the classical and lectin complement pathways comprising administering ~~an antibody that binds C2a or the C2a portion of C2~~ the antibody of claim 19 or claim 20.

30. (Previously Presented) The method of claim 28, wherein the inhibition of complement activation is determined *in vitro*.

31. Canceled

32. (Currently Amended) A method of treating a disease or condition that is mediated by excessive or uncontrolled activation of the complement system comprising administering, *in vivo* or *ex vivo*, the antibody of ~~any one of claims 19, 20 or 21~~ claim 19 or claim 20.

33. (Previously Presented) The method of claim 32, wherein the antibody is administered by intravenous infusion, intravenous bolus injection, intraperitoneal, intradermal, intramuscular, subcutaneous, intranasal, intratracheal, intraspinal, intracranial, or orally.

34. (Previously Presented) A diagnostic method comprising the detection of the amount of C2 or C2a present in a sample with the antibody of claim 19.

35. (Previously Presented) The diagnostic method of claim 34, wherein the antibody is the monoclonal antibody 175-62.